149402-51-7
光克洛(14-Ethyl-9-(1-(hexyloxy)ethyl)-4,8,13,18-tetramethyl-20-oxo-3-phorbine propanoic acid)
CAS: 149402-51-7
化学式: C39H48N4O4
| 中文名 | 光克洛 |
| 英文名 | 14-Ethyl-9-(1-(hexyloxy)ethyl)-4,8,13,18-tetramethyl-20-oxo-3-phorbine propanoic acid |
| 别名 | 光克洛 |
| 英文别名 | HPPH Sulcardine Photochlor (HPPH) 2-(1-hexyloxyethyl)-2-devinyl pyropheophorbide-a 3-Devinyl-3-(1'-hexyloxy)ethylpyropheophorbide A 14-Ethyl-9-(1-(hexyloxy)ethyl)-4,8,13,18-tetramethyl-20-oxo-3-phorbine propanoic acid (3S,4S)-14-Ethyl-9-[1-(hexyloxy)ethyl]-4,8,13,18-tetramethyl-20-oxo-3-phorbinepropanoic acid 3-Phorbinepropanoic acid, 14-ethyl-9-[1-(hexyloxy)ethyl]-4,8,13,18 -tetramethyl-20-oxo-, (3S,4S)- |
| CAS | 149402-51-7 |
| 化学式 | C39H48N4O4 |
| 分子量 | 636.36 |
| 密度 | 1.184 |
| 沸点 | 992.5±65.0 °C(Predicted) |
| 溶解度 | 可溶于DMSO，不溶于水 |
| 存储条件 | -20℃ |
| 物化性质 | 生物活性 HPPH (Photochlor) 是第二代光敏剂，用于光动力疗法 (PDT)。 |
| 体外研究 | Fluorescence image of 4T1 cells incubated with 0.49 µg/mL GO-PEG, 1 μM HPPH (free HPPH) or equivalent amount of GO-PEG-HPPH (1 µM HPPH and 0.49 µg/mL GO-PEG) after 24 h. The cellular uptake of GO-PEG-HPPH and HPPH is investigated with 4T1 murine mammary cancer cells. The cells are incubated with GO-PEG-HPPH and free HPPH at equivalent HPPH concentration (1 µM) for 24 h and then observed with a confocal microscope. Cells treated with GO-PEG-HHPH shows stronger fluorescence signal than those treated with free HPPH. In fact, the fluorescence of HPPH is rather weak. |
| 体内研究 | Tumors are treated with an immune-enhancing PDT regimen followed by a tumor-controlling PDT regimen can leads to enhancement of anti-tumor immunity, while retaining effective control of primary tumor growth. To test this hypothesis, a combination treatment regimen is devised in which Colo26-HA tumor-bearing BALB/c mice are treated with a HPPH-PDT regimen known to lead to enhanced anti-tumor immunity (0.4 μmoles/kg HPPH followed 18 h later by illumination with 665 nm light for a total dose of 48 J/cm 2 ). Following illumination, mice are rested for 9 days; on the ninth day, mice are injected with HPPH. On day 10 following the first treatment, tumors are treated with a tumor control treatment regimen (illumination with 665 nm light for a total dose of 132 J/cm 2 given). |
| 参考资料 展开查看 | 1: Sun G, Anderson MA, Gorospe EC, Leggett CL, Lutzke LS, Wong Kee Song LM, Levy M, Wang KK. Synergistic effects of photodynamic therapy with HPPH and gemcitabine in pancreatic cancer cell lines. Lasers Surg Med. 2012 Nov;44(9):755-61. doi: 10.1002/lsm.22073. Epub 2012 Sep 27. PubMed PMID: 23018618. 2: Nava HR, Allamaneni SS, Dougherty TJ, Cooper MT, Tan W, Wilding G, Henderson BW. Photodynamic therapy (PDT) using HPPH for the treatment of precancerous lesions associated with Barrett's esophagus. Lasers Surg Med. 2011 Sep;43(7):705-12. doi: 10.1002/lsm.21112. PubMed PMID: 22057498; PubMed Central PMCID: PMC3218433. 3: Srivatsan A, Ethirajan M, Pandey SK, Dubey S, Zheng X, Liu TH, Shibata M, Missert J, Morgan J, Pandey RK. Conjugation of cRGD peptide to chlorophyll a based photosensitizer (HPPH) alters its pharmacokinetics with enhanced tumor-imaging and photosensitizing (PDT) efficacy. Mol Pharm. 2011 Aug 1;8(4):1186-97. doi: 10.1021/mp200018y. Epub 2011 Jul 1. PubMed PMID: 21702452; PubMed Central PMCID: PMC3148296. 4: Sunar U, Rohrbach D, Rigual N, Tracy E, Keymel K, Cooper MT, Baumann H, Henderson BH. Monitoring photobleaching and hemodynamic responses to HPPH-mediated photodynamic therapy of head and neck cancer: a case report. Opt Express. 2010 Jul 5;18(14):14969-78. doi: 10.1364/OE.18.014969. PubMed PMID: 20639983; PubMed Central PMCID: PMC2964147. |
149402-51-7 - 配置溶液浓度参考
| 1mg | 5mg | 10mg | |
|---|---|---|---|
| 1 mM | 1.571 ml | 7.857 ml | 15.714 ml |
| 5 mM | 0.314 ml | 1.571 ml | 3.143 ml |
| 10 mM | 0.157 ml | 0.786 ml | 1.571 ml |
| 5 mM | 0.031 ml | 0.157 ml | 0.314 ml |
最后更新：2024-01-02 23:10:35
供应商列表
您刚刚浏览过
你知道吗？
微信搜索化工百科或扫描下方二维码，添加化工百科小程序，随时随地查信息！